WHO ICTRP trial
Bevacizumab modulation of telangiectasia in irradiated rectal cancer patients.
NL-OMON22711 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON22711 |
|---|---|
| Public title | Bevacizumab modulation of telangiectasia in irradiated rectal cancer patients. |
| Scientific title | Bevacizumab modulation of telangiectasia. |
| Primary sponsor | NKI-AVL (Netherlands ancer Institute) |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Observational non invasive |
| Conditions | rectal cancer bevacizumab telangiectasia radiotherapy |
| Interventions | 2 sigmoidoscopies for mucosal biopsy sampling. |
| Registration date | Dec 14, 2011 |
| Target size | 20 |
| Secondary IDs | NL3047;NTR3195;NL37827.031.11;ISRCTN wordt niet meer aangevraagd. |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: